Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test replace scans for pancreatic cancer patients?

NCT ID NCT07122466

Knowledge-focused Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test that measures tumor DNA (ctDNA) can predict how well chemotherapy is working in people with advanced pancreatic cancer. Researchers will compare the blood test results with CT scans taken before and two months after starting treatment. The goal is to see if the blood test is a reliable alternative to imaging, which could make monitoring easier for patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simpler blood test to monitor treatment response in pancreatic cancer, reducing the need for frequent CT scans.
What could go wrong
This is a very small pilot study with only 24 participants, so results may not apply to everyone. It's observational, meaning it won't directly improve treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

24 people

The number who actually took part.

Started

May 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The proposed sample size of 20 subjects is based on feasibility and availability of resources and not on a formal power calculation. The number of subjects is small, so as to quickly gather data that could inform a larger study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Prior/Concurrent Therapy Criteria 1. Patients must be initiating a new treatment regimen for pancreatic cancer at the time of their initiation in the study 2. Patients must have cytologic or histologic confirmation of pancreatic cancer 3. Patients must have measurable radiographic evidence of metastatic disease 4. Patients must be ≥18 years of age 5. Patients must have an ECOG Performance Status 0-2. 6. Patients must have adequate organ function for delivery of chemotherapy as evidenced by the following: Hgb ≥8 g/dL, platelets ≥ 75 7. Patients must not have renal dysfunction that would prevent administration of IV contrast for radiographic assessment. Regulatory Criteria 8. Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines. 9. Patients of all races, genders, \& ethnicities are eligible. Exclusion Criteria: No exclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metastatic pancreatic cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metastatic pancreatic cancer

Contacts and locations

Locations

  • Zuckerberg Cancer Center

    New Hyde Park, New York, 11042, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.